A Case Report of Primary Pulmonary Synovial Sarcoma with Postoperative Multiple Metastases Treated with Apatinib.
10.3779/j.issn.1009-3419.2018.11.11
- Author:
Di ZHANG
1
;
Chufeng ZHANG
2
;
Qisen GUO
2
Author Information
1. Shandong Cancer Hospital Affiliated to Shandong University, Shandong University, Jinan 250117, China.
2. Shandong Cancer Hospital affiliated to Shandong University, Shandong Academy of Medical Sciences, Shandong Cancer Hospital
and Institute, Jinan 250117, China.
- Publication Type:Case Reports
- Keywords:
Apatinib;
Lung neoplasms;
Primary pulmonary synovial sarcoma
- MeSH:
Humans;
Lung Neoplasms;
drug therapy;
pathology;
surgery;
Male;
Middle Aged;
Neoplasm Metastasis;
Postoperative Period;
Pyridines;
therapeutic use;
Sarcoma, Synovial;
drug therapy;
pathology;
surgery
- From:
Chinese Journal of Lung Cancer
2018;21(11):880-884
- CountryChina
- Language:Chinese
-
Abstract:
Primary pulmonary synovial sarcoma is a rare pulmonary malignant tumor originated from primitive mesenchymal, which has short overall survival and poor prognosis. Related case reports are lacked at home and abroad. In recent years, the development of targeted therapy has brought remarkable benefits to cancer patients. Apatinib (Hengrui Pharmaceutical Co. Ltd, Jiangsu, People's Republic of China) is a small molecule vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, which selectively inhibits VEGFR-2 and blocks the VEGF signal pathway, then strongly inhibiting the tumor angiogenesis. Apatinib has shown favorable therapeutic effect and acceptable toxicity on various tumors. Here we report a case of primary pulmonary synovial sarcoma with postoperative multiple metastases treated with apatinib, in order to provide a new considerable treatment.
.
